Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$2.92
-1.0%
$3.43
$1.24
$4.08
$774.22M1.024.13 million shs2.48 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$3.59
-1.4%
$3.83
$2.90
$11.16
$316.85M0.183.64 million shs2.05 million shs
Geron Corporation stock logo
GERN
Geron
$1.27
$1.33
$1.09
$4.83
$810.28M0.6311.99 million shs4.27 million shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$19.25
+3.4%
$8.87
$2.92
$19.69
$135.14M-1.82110,037 shs492,710 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.37
-0.1%
$104.80
$27.54
$106.45
$9.17B0.142.17 million shs1.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-0.34%-9.23%-17.60%+102.05%
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-3.70%+0.28%-47.02%-53.81%
Geron Corporation stock logo
GERN
Geron
0.00%-9.29%-12.41%-18.06%-71.84%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+27.97%+123.80%+329.03%+215.06%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%+0.11%+1.10%+14.81%+257.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$2.92
-1.0%
$3.43
$1.24
$4.08
$774.22M1.024.13 million shs2.48 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$3.59
-1.4%
$3.83
$2.90
$11.16
$316.85M0.183.64 million shs2.05 million shs
Geron Corporation stock logo
GERN
Geron
$1.27
$1.33
$1.09
$4.83
$810.28M0.6311.99 million shs4.27 million shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$19.25
+3.4%
$8.87
$2.92
$19.69
$135.14M-1.82110,037 shs492,710 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.37
-0.1%
$104.80
$27.54
$106.45
$9.17B0.142.17 million shs1.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-0.34%-9.23%-17.60%+102.05%
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-3.70%+0.28%-47.02%-53.81%
Geron Corporation stock logo
GERN
Geron
0.00%-9.29%-12.41%-18.06%-71.84%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+27.97%+123.80%+329.03%+215.06%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%+0.11%+1.10%+14.81%+257.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00
Buy$6.75131.16% Upside
Altimmune, Inc. stock logo
ALT
Altimmune
2.57
Moderate Buy$17.40384.68% Upside
Geron Corporation stock logo
GERN
Geron
2.29
Hold$3.79198.09% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.20
Buy$21.7512.99% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.14
Hold$109.002.47% Upside

Current Analyst Ratings Breakdown

Latest ALT, VRNA, AKBA, GERN, and KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$15.00 ➝ $33.00
9/8/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$30.00
9/3/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/13/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/13/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
8/13/2025
Altimmune, Inc. stock logo
ALT
Altimmune
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$26.00 ➝ $24.00
8/13/2025
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $18.00
8/8/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/14/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral$90.00 ➝ $107.00
7/11/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
7/10/2025
Altimmune, Inc. stock logo
ALT
Altimmune
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$203.73M3.80N/AN/A($0.23) per share-12.70
Altimmune, Inc. stock logo
ALT
Altimmune
$20K15,842.67N/AN/A$1.74 per share2.06
Geron Corporation stock logo
GERN
Geron
$164.45M4.93N/AN/A$0.46 per share2.76
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M34.74N/AN/A$2.02 per share9.53
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M216.84N/AN/A$2.56 per share41.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$0.99N/A3,545.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)

Latest ALT, VRNA, AKBA, GERN, and KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million
8/8/2025Q2 2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$1.82-$1.71+$0.11-$1.71N/AN/A
8/6/2025Q2 2025
Geron Corporation stock logo
GERN
Geron
-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.61
1.98
1.84
Altimmune, Inc. stock logo
ALT
Altimmune
0.09
20.44
20.44
Geron Corporation stock logo
GERN
Geron
0.46
7.87
6.79
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.19
2.10
2.10
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.87
10.71
10.54

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Geron Corporation stock logo
GERN
Geron
73.71%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
85.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430265.15 million257.19 millionOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5088.26 million84.37 millionOptionable
Geron Corporation stock logo
GERN
Geron
70638.02 million590.68 millionOptionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
307.02 million6.44 millionNot Optionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3086.19 million82.06 millionOptionable

Recent News About These Companies

Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$2.92 -0.03 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$2.94 +0.02 (+0.86%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Altimmune stock logo

Altimmune NASDAQ:ALT

$3.59 -0.05 (-1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$3.61 +0.02 (+0.56%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Geron stock logo

Geron NASDAQ:GERN

$1.27 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.27 +0.00 (+0.39%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$19.25 +0.63 (+3.38%)
Closing price 04:00 PM Eastern
Extended Trading
$19.27 +0.02 (+0.13%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$106.37 -0.06 (-0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$105.73 -0.64 (-0.61%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.